Navigation Links
Clinical Data from NewLink Genetics' HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy
Date:12/13/2012

AMES, Iowa, Dec. 13, 2012 /PRNewswire/ -- NewLink Genetics Corporation (Nasdaq: NLNK) today announced that the results of a  Phase 1 dose escalation study with its proprietary HyperAcute Prostate Cancer Immunotherapy were published in the Journal of Immunotherapy.  The article, entitled "Cellular Immunotherapy Study of Prostate Cancer Patients and Resulting IgG Responses to Peptide Epitopes Predicted From Prostate Tumor-associated Autoantigens," is featured in the current edition of the Journal.

The study was conducted at the University of Nebraska Medical Center and included eight patients.  Patients were scheduled to receive a priming dose on day one, followed by eleven boost doses every two weeks and patients received up to 12 intradermal vaccinations at doses ranging from 30 million to 500 million cells per injection. Patients were tested for safety, immunological and clinical responses arising after immunotherapy.  

The study demonstrated that the immunotherapy was safe, and that the first immunization differentially increased the anti-alphaGal IgG response in all patients compared with baseline levels. These data indicated that administration of HyperAcute-Prostate immunotherapy increases the immune response against alphaGal epitopes, demonstrating the immunogenicity of the vaccine in prostate cancer patients.

The patients that received the highest dose of immunotherapy developed antibody responses against prostate tumor-associated antigens that were not seen in a control group of untreated volunteers.  Data  demonstrated that 37.5 percent (3/8) of patients responded with Prostate Specific Antigen (PSA) level stabilization for more than 100 days.  

The adverse events data reported in this publication confirm the safety of this immunotherapy, consistent with previous studies on the safety of alph
'/>"/>

SOURCE NewLink Genetics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
2. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
3. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
4. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
5. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. New Clinical Endocrinology Guidelines Support Lp-PLA2 Measurement For Risk Assessment of Coronary Artery Disease
8. First Patient Treated in U.S. Clinical Study of Cohera Medicals TissuGlu® Surgical Adhesive
9. Michael J. Fox Foundation-Funded Study Identifies Best Dyskinesia Clinical Rating Scale
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( ... "Dental Consumables Market - Global Industry Analysis, Size, Share, ... to their offering. (Logo: ... which are used on patients in order to treat ...
(Date:1/15/2014)...  Novation, the leading health care supply chain expertise, analytics ... (VAR) national contracts that expand its portfolio to provide ... costs. These include manufacturer product and service agreements, as ... ongoing IT consulting support. New Novation ...
(Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer for ... As a result of the waiver, the transaction is ... the tender offer on January 24, 2014 following the currently scheduled ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... has,received a Complete Response Letter from the U.S. ... Application (NDA) for a,controlled-release form of hydrocodone with ... will discuss the letter with,the FDA, and will ... seeking the approval of controlled-release hydrocodone with,acetaminophen as ...
... 20 Alsius Corporation,(Nasdaq: ALUS ), the ... announced that four scientific,posters featuring both patient cases ... utilized will be presented this week at the ... in Orlando., Dr. Arie Blitz, Director of ...
Cached Medicine Technology:Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting 2Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting 3
(Date:4/23/2014)... NY, April 23, 2014Men whose testosterone falls below normal ... to be overweight and have heart disease and type ... identify testosterone-deficient men for further testing and possible treatment ... Men,s Health , a peer-reviewed publication from Mary Ann ... the Journal of Men,s Health website at ...
(Date:4/23/2014)... of probiotics, antioxidants and other nutritional compounds, more and ... is getting in on the action. But legitimate skepticism ... industry is responding with clinical research to shore up ... Chemical & Engineering News (C&EN), the weekly news ... Bomgardner, a senior editor at C&EN, writes that about ...
(Date:4/23/2014)... team of scientists led by a researcher from the ... National University of Singapore has identified the cancer specific ... up the possibility of developing new drugs for the ... , The research group, led by Dr Chan Shing ... the first time that a cancer-specific variant of a ...
(Date:4/23/2014)... the depletion of self-control, according to research published in ... for Psychological Science. , Self-control can be difficult ... on a boring textbook are hard things to do. ... Exerting self-control for a long period seems to "deplete" ... , "It is as if self-control is a limited ...
(Date:4/22/2014)... New Jersey Institute of Technology (NJIT) today to ... launch of the New Jersey Innovation Institute (NJII), ... for business innovation through the leveraging of industry, ... Senator Cory Booker, Panasonic Corp. of North America ... Governor Kim Guadagno, New Jersey Secretary of Higher ...
Breaking Medicine News(10 mins):Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
... an interesting,snapshot of Minnesotans, changing driving habits, retail ... percent decline compared to sales in July 2007.,According ... motorists,bought 211,982,582 gallons of gasoline in July, compared ... the amount of ethanol-based,E85 sold during the same ...
... medical student in the country. That,s because the three-part ... delivered in a new way: by listening to a ... an Achilles heel in the medical field. , ... test know they don,t have this auditory skill," says Michael ...
... Trevino, master permanent make-up artist and educator joins Nouveau Cosmetique ... advance the education of permanent cosmetic professionals in the US. ... ... August 25, 2008 -- Nouveau Cosmetique USA, Inc., the exclusive ...
... (PTCB) Exhibits at this week,s National Association of Chain Drug ... solutions for enhanced patient safety and the benefits of pharmacy ... ... CA (PRWEB) August 25, 2008 - The https://www.ptcb.org/ ...
... HMS Holdings Corp. (Nasdaq:,HMSY) today announced that it ... which will be held September 3-5, 2008 at the,Four ... and Chief Financial Officer of HMS Holdings Corp.,will present ... A live broadcast of the Company,s presentation can ...
... 96 on the, 2008 Inc. 500, with three-year sales growth ... ... Inc. magazine today ranked The,Coding Source No. 96 on its 27th ... list is the most,comprehensive look at the most important segment of the ...
Cached Medicine News:Health News:Listen up! 2Health News:Master Permanent Make-up Artist and Educator Sulema Trevino Joins Nouveau Cosmetique Team 2Health News:Pharmacy Technician Certification Board (PTCB) Exhibits at 2008 NACDS Pharmacy & Technology Conference 2Health News:Pharmacy Technician Certification Board (PTCB) Exhibits at 2008 NACDS Pharmacy & Technology Conference 3Health News:The Coding Source Named to Inc. Magazine's 27th Annual List of America's 500 Fastest-Growing Private Companies 2Health News:The Coding Source Named to Inc. Magazine's 27th Annual List of America's 500 Fastest-Growing Private Companies 3
Finally, a camera that sees the way you do!,Combined with the MicroLux DVR (Digital Video Recorder), the MicroLux Headlight Camera System gives you an entirely new way to visualize, edit, share and...
... This latest sensor array with ... inter-channel spacing of just 2.2 ... is particularly useful when using ... Synthetic Aperture Magnetometry (SAM) or ...
... achieved using an increased tilt angle of ... bed. The patient preparation can be carried ... of an emergency the patient can be ... e.g. resuscitation purposes. The integrated neck support ...
... Magnes 1300 C is ideal for evaluating a ... other parts of the body. Often referred to ... including magnetocardiography, gastrointestinal tract, fetal, spinal cord and ... 1300 C, with its 67 detector coils, covers ...
Medicine Products: